Publications by authors named "Paul Bien"

Claim this Profile
activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Michael Pfaller, Michael Huband, Paul A Bien, Cecilia G Carvalhaes, Abby Klauer

Antimicrob Agents Chemother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
Peter G Pappas, Jose A Vazquez, Ilana Oren, Galia Rahav, Mickael Aoun, Paul A Bien

J Antimicrob Chemother· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris Results from a Phase 2 Trial.
Jose A Vazquez, Peter G Pappas, Kenneth Boffard, Fathima Paruk, Paul A Bien

Antimicrob Agents Chemother· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019).
Michael A Pfaller, Michael D Huband, Robert K Flamm, Paul A Bien, Mariana Castanheira

J Glob Antimicrob Resist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Daniel F Sahm, Jennifer Deane, Paul A Bien, Jeffrey B Locke, Douglas E Zuill

Diagn Microbiol Infect Dis· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
Gary Zurenko, Paul Bien, Mekki Bensaci, Hina N Patel, Grace Thorne

Ann Clin Microbiol Antimicrob· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of digital planimetry and ruler technique to measure ABSSSI lesion sizes in the ESTABLISH-1 study.
Paul Bien, Carisa De Anda, Philippe Prokocimer

Surg Infect (Larchmt)· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
Shawn D Flanagan, Paul A Bien, Kelly A Muñoz, Sonia L Minassian, Philippe G Prokocimer

Pharmacotherapy· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Philippe Prokocimer, Paul Bien, Carisa Deanda, Chris M Pillar, Ken Bartizal

Antimicrob Agents Chemother· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis